FINANCINGS
AMO Pharma Ltd. said it raised $25 million in private equity financing.
Apitope Ltd. raised $13.5 million in a series B financing.
Asceneuron SA closed a series A financing of $30.6 million led by Sofinnova Partners.
Biotime Inc. will sell up to $20.7 million of its common shares in a registered direct offering to select investment funds in Israel.
Corvus Pharmaceuticals Inc. raised $75 million from a series B round of financing.
CTI Biopharma Corp. said institutional investors will purchase 10 million shares of its common stock in a registered direct offering for gross proceeds of about $15.7 million.
Edge Therapeutics Inc. said it priced its IPO of 7.3 million shares at $11 per share.
Intra-Cellular Therapies Inc. completed a public offering for gross proceeds of approximately $345 million.
Medgenics Inc. priced a public offering with gross proceeds expected to be approximately $40 million.
Mirna Therapeutics Inc. said it priced its IPO, selling of 6.25 million shares at $7 each to generate approximately $44 million.
Myokardia Inc. has filed to raise up to $86.3 million through an IPO on Nasdaq.
Neon Therapeutics Inc. raised $55 million in a series A round.
Pharmalink AB has raised $12 million from its existing investors.
Therachon SAS raised $35 million in a series A financing round.
Tunitas Therapeutics Inc. said it closed a $10 million series A venture financing.
DEALS
Aelan Cell Technologies entered an agreement with the Gladstone Institutes to further its studies on stem cell rejuvenation.
Amicus Therapeutics Inc. has completed its acquisition of Scioderm Inc.
Biomarin Pharmaceutical Inc. will regain global rights to the phenylketonuria drugs Kuvan and Peg-Pal from Merck Serono.
Bristol-Myers Squibb Co. and Moffitt Cancer Center entered into a collaboration agreement as part of BMS's immuno-oncology rare population malignancy program in the U.S
Carsgen Therapeutics entered a five-year research and development agreement with the Shanghai Cancer Institute for the advancement of its CAR-T cancer immunotherapeutics.
Chromocell Corp. has inked a potential $500 million deal with Astellas Pharma Inc.
Cloud Pharmaceuticals Inc. and Therametrics Holding AG are collaborating to design and develop therapeutics for orphan central nervous system diseases and other indications.
Intrexon Corp. formed a new collaboration with Ziopharm Oncology Inc. focused on immunotherapies to treat and prevent graft-vs.-host disease.
Numedii Inc. formed a research alliance with Allergan plc to explore new therapeutic options for the potential treatment of psoriasis.
Smartox Biotechnology inked a research collaboration with Xenon Pharmaceuticals Inc. to identify venom toxins that selectively modulate specific ion channels.
Teva Pharmaceutical Industries Ltd. entered a definitive agreement to acquire Gecko Health Innovations Inc.
Xoma Corp. struck an exclusive licensing deal with Novartis AG that gives it rights for development of its anti-transforming growth factor-beta antibody program.
. . . AND MORE
New World Health Organization recommendations remove all eligibility limitations on antiretroviral therapy for people with HIV.
Sanofi SA said the FDA accepted the new drug application for lixisenatide, an investigational once-daily prandial GLP-1 receptor agonist to treat adults with type 2 diabetes mellitus.
Taiho Oncology Inc. won U.S. FDA approval for its oral combination anticancer drug TAS-102 (trifluridine hydrochloride) for refractory metastatic colorectal cancer.
Verastem Inc. halted its phase II study, COMMAND, of lead candidate VS-6063 (defactinib) for futility in malignant pleural mesothelioma.